Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cymabay Therapeutics, Inc. (NONE) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cymabay Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1042074.
Total stock buying since 2014: $6,648,967.
Total stock sales since 2014: $27,129,324.
Total stock option exercises since 2014: $3,524,732.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 45,403 | $1,124,300 | 87,227 | $537,513 |
| 2023 | 0 | $0 | 555,345 | $7,849,673 | 622,390 | $2,779,966 |
| 2022 | 71,301 | $160,836 | 0 | $0 | 0 | $0 |
| 2019 | 10,000 | $49,155 | 11,675 | $105,331 | 11,675 | $61,293 |
| 2018 | 25,000 | $222,650 | 1,036,961 | $12,522,130 | 20,000 | $103,750 |
| 2017 | 178,846 | $1,187,804 | 624,769 | $5,399,697 | 18,000 | $42,210 |
| 2016 | 88,000 | $150,539 | 0 | $0 | 0 | $0 |
| 2015 | 1,709,500 | $4,803,583 | 46,729 | $128,193 | 0 | $0 |
| 2014 | 10,000 | $74,400 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-03 | 0 | $0 | 0 | $0 | 41,824 | $329,991 |
| 2024-02 | 0 | $0 | 6,000 | $191,850 | 6,000 | $27,780 |
| 2024-01 | 0 | $0 | 39,403 | $932,450 | 39,403 | $179,742 |
| 2023-12 | 0 | $0 | 108,694 | $2,269,540 | 108,694 | $557,606 |
| 2023-11 | 0 | $0 | 16,342 | $294,187 | 33,842 | $131,785 |
| 2023-10 | 0 | $0 | 91,604 | $1,296,030 | 109,104 | $508,095 |
| 2023-09 | 0 | $0 | 90,667 | $1,496,471 | 107,212 | $373,439 |
| 2023-08 | 0 | $0 | 47,691 | $567,665 | 63,191 | $313,870 |
| 2023-07 | 0 | $0 | 26,749 | $307,575 | 26,749 | $123,445 |
| 2023-06 | 0 | $0 | 26,749 | $227,634 | 26,749 | $123,445 |
| 2023-05 | 0 | $0 | 26,749 | $249,223 | 26,749 | $123,445 |
| 2023-04 | 0 | $0 | 120,000 | $1,140,450 | 120,000 | $524,399 |
| 2023-03 | 0 | $0 | 100 | $898 | 100 | $437 |
| 2022-06 | 51,301 | $100,036 | 0 | $0 | 0 | $0 |
| 2022-01 | 20,000 | $60,800 | 0 | $0 | 0 | $0 |
| 2019-10 | 5,000 | $21,500 | 0 | $0 | 0 | $0 |
| 2019-09 | 5,000 | $27,655 | 0 | $0 | 0 | $0 |
| 2019-02 | 0 | $0 | 11,675 | $105,331 | 11,675 | $61,293 |
| 2018-12 | 10,000 | $65,400 | 142,381 | $1,123,615 | 0 | $0 |
| 2018-10 | 5,000 | $49,500 | 0 | $0 | 0 | $0 |
| 2018-08 | 0 | $0 | 5,000 | $65,000 | 5,000 | $25,000 |
| 2018-07 | 5,000 | $54,500 | 0 | $0 | 0 | $0 |
| 2018-06 | 0 | $0 | 920 | $11,509 | 0 | $0 |
| 2018-05 | 5,000 | $53,250 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-03-13 | Quinlan Paul T (General Counsel) | Option Ex | 41,824 | 7.89 | 329,991 |
| 2024-02-12 | Dorling Janet (Director) | Sale | 6,000 | 31.98 | 191,850 |
| 2024-02-12 | Dorling Janet (Director) | Option Ex | 6,000 | 4.63 | 27,780 |
| 2024-01-19 | Mcwherter Charles (President of R&D) | Sale | 18,403 | 23.67 | 435,599 |
| 2024-01-19 | Mcwherter Charles (President of R&D) | Option Ex | 18,403 | 5.26 | 96,762 |
| 2024-01-16 | Menold Daniel (Vice President, Finance) | Sale | 10,000 | 23.58 | 235,810 |
| 2024-01-16 | Menold Daniel (Vice President, Finance) | Option Ex | 10,000 | 4.05 | 40,500 |
| 2024-01-16 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 23.58 | 117,899 |
| 2024-01-16 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2024-01-10 | Dorling Janet (Director) | Sale | 6,000 | 23.86 | 143,142 |
| 2024-01-10 | Dorling Janet (Director) | Option Ex | 6,000 | 4.63 | 27,780 |
| 2023-12-18 | Mcwherter Charles (President of R&D) | Sale | 11,332 | 21.48 | 243,445 |
| 2023-12-18 | Mcwherter Charles (President of R&D) | Option Ex | 11,332 | 5.00 | 56,660 |
| 2023-12-15 | Menold Daniel (Vice President, Finance) | Sale | 21,497 | 21.99 | 472,654 |
| 2023-12-15 | Menold Daniel (Vice President, Finance) | Option Ex | 21,497 | 6.24 | 134,141 |
| 2023-12-15 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 21.98 | 109,905 |
| 2023-12-15 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-12-11 | Dorling Janet (Director) | Sale | 6,000 | 20.07 | 120,420 |
| 2023-12-11 | Dorling Janet (Director) | Option Ex | 6,000 | 4.63 | 27,780 |
| 2023-12-11 | Shah Sujal (Chief Executive Officer) | Sale | 64,865 | 20.40 | 1,323,116 |
| 2023-12-11 | Shah Sujal (Chief Executive Officer) | Option Ex | 64,865 | 5.00 | 324,325 |
| 2023-11-17 | Mcwherter Charles (President of R&D) | Sale | 11,342 | 18.28 | 207,297 |
| 2023-11-17 | Mcwherter Charles (President of R&D) | Option Ex | 11,342 | 5.00 | 56,710 |
| 2023-11-15 | Menold Daniel (Vice President, Finance) | Option Ex | 17,500 | 3.45 | 60,375 |
| 2023-11-15 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 17.38 | 86,890 |
| 2023-11-15 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-10-18 | Mcwherter Charles (President of R&D) | Sale | 21,743 | 14.07 | 305,945 |
| 2023-10-18 | Mcwherter Charles (President of R&D) | Option Ex | 21,743 | 5.00 | 108,715 |
| 2023-10-16 | Menold Daniel (Vice President, Finance) | Option Ex | 17,500 | 3.45 | 60,375 |
| 2023-10-16 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 13.76 | 68,800 |
| 2023-10-16 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-10-09 | Shah Sujal (Chief Executive Officer) | Sale | 64,861 | 14.20 | 921,285 |
| 2023-10-09 | Shah Sujal (Chief Executive Officer) | Option Ex | 64,861 | 5.00 | 324,305 |
| 2023-09-29 | Emster Kurt Von (Director) | Sale | 15,921 | 15.68 | 249,673 |
| 2023-09-29 | Emster Kurt Von (Director) | Option Ex | 15,921 | 5.00 | 79,605 |
| 2023-09-18 | Mcwherter Charles (President of R&D) | Sale | 21,746 | 16.22 | 352,741 |
| 2023-09-18 | Mcwherter Charles (President of R&D) | Option Ex | 21,746 | 5.00 | 108,730 |
| 2023-09-15 | Menold Daniel (Vice President, Finance) | Option Ex | 16,545 | 1.77 | 29,284 |
| 2023-09-15 | Quinlan Paul T (General Counsel) | Sale | 53,000 | 16.87 | 894,057 |
| 2023-09-15 | Quinlan Paul T (General Counsel) | Option Ex | 53,000 | 2.94 | 155,820 |
| 2023-08-18 | Mcwherter Charles (President of R&D) | Sale | 21,746 | 11.47 | 249,361 |
| 2023-08-18 | Mcwherter Charles (President of R&D) | Option Ex | 21,746 | 5.00 | 108,730 |
| 2023-08-15 | Menold Daniel (Vice President, Finance) | Option Ex | 15,500 | 5.53 | 85,715 |
| 2023-08-15 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 11.91 | 59,550 |
| 2023-08-15 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-08-09 | Menold Daniel (Vice President, Finance) | Sale | 20,945 | 12.35 | 258,754 |
| 2023-08-09 | Menold Daniel (Vice President, Finance) | Option Ex | 20,945 | 5.00 | 104,725 |
| 2023-07-18 | Mcwherter Charles (President of R&D) | Sale | 21,749 | 11.43 | 248,525 |
| 2023-07-18 | Mcwherter Charles (President of R&D) | Option Ex | 21,749 | 5.00 | 108,745 |
| 2023-07-14 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 11.81 | 59,050 |
| 2023-07-14 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-06-30 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 10.05 | 50,250 |
| 2023-06-30 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-06-20 | Mcwherter Charles (President of R&D) | Sale | 21,749 | 8.16 | 177,384 |
| 2023-06-20 | Mcwherter Charles (President of R&D) | Option Ex | 21,749 | 5.00 | 108,745 |
| 2023-05-18 | Mcwherter Charles (President of R&D) | Sale | 21,749 | 9.08 | 197,393 |
| 2023-05-18 | Mcwherter Charles (President of R&D) | Option Ex | 21,749 | 5.00 | 108,745 |
| 2023-05-15 | Quinlan Paul T (General Counsel) | Sale | 5,000 | 10.37 | 51,830 |
| 2023-05-15 | Quinlan Paul T (General Counsel) | Option Ex | 5,000 | 2.94 | 14,700 |
| 2023-04-17 | Kim Dennis D (Chief Medical Officer) | Sale | 112,219 | 9.54 | 1,070,569 |
| 2023-04-17 | Kim Dennis D (Chief Medical Officer) | Option Ex | 112,219 | 4.37 | 490,397 |
| 2023-04-13 | Kim Dennis D (Chief Medical Officer) | Sale | 7,781 | 8.98 | 69,881 |
| 2023-04-13 | Kim Dennis D (Chief Medical Officer) | Option Ex | 7,781 | 4.37 | 34,002 |
| 2023-03-28 | Kim Dennis D (Chief Medical Officer) | Sale | 100 | 8.98 | 898 |
| 2023-03-28 | Kim Dennis D (Chief Medical Officer) | Option Ex | 100 | 4.37 | 437 |
| 2022-06-06 | Shah Sujal (Chief Executive Officer) | Buy | 51,301 | 1.95 | 100,036 |
| 2022-01-19 | Kim Dennis D (Chief Medical Officer) | Buy | 20,000 | 3.04 | 60,800 |
| 2019-10-10 | Shah Sujal (Chief Executive Officer) | Buy | 5,000 | 4.30 | 21,500 |
| 2019-09-23 | Shah Sujal (Chief Executive Officer) | Buy | 3,100 | 5.55 | 17,205 |
| 2019-09-20 | Shah Sujal (Chief Executive Officer) | Buy | 1,900 | 5.50 | 10,450 |
| 2019-02-07 | Goldfischer Carl (Director) | Sale | 11,675 | 9.02 | 105,331 |
| 2019-02-07 | Goldfischer Carl (Director) | Option Ex | 11,675 | 5.25 | 61,293 |
| 2018-12-21 | Shah Sujal (Chief Executive Officer) | Buy | 10,000 | 6.54 | 65,400 |
| 2018-12-18 | Emster Kurt Von | Sale | 53,492 | 7.43 | 397,392 |
| 2018-12-17 | Emster Kurt Von | Sale | 88,889 | 8.17 | 726,223 |
| 2018-10-15 | Shah Sujal (Chief Executive Officer) | Buy | 5,000 | 9.90 | 49,500 |
| 2018-08-29 | Menold Daniel (Vice President, Finance) | Sale | 5,000 | 13.00 | 65,000 |
| 2018-08-29 | Menold Daniel (Vice President, Finance) | Option Ex | 5,000 | 5.00 | 25,000 |
| 2018-07-27 | Shah Sujal (Chief Executive Officer) | Buy | 5,000 | 10.90 | 54,500 |
| 2018-06-05 | Emster Kurt Von | Sale | 920 | 12.51 | 11,509 |
| 2018-05-11 | Shah Sujal (Chief Executive Officer) | Buy | 5,000 | 10.65 | 53,250 |
| 2018-03-22 | Goldfischer Carl (Director) | Sale | 15,000 | 13.03 | 195,375 |
| 2018-03-22 | Goldfischer Carl (Director) | Option Ex | 15,000 | 5.25 | 78,750 |
| 2018-03-05 | Emster Kurt Von | Sale | 13,353 | 15.51 | 207,105 |
| 2018-02-15 | Emster Kurt Von | Sale | 68,712 | 14.49 | 995,636 |
| 2018-02-14 | Emster Kurt Von | Sale | 162,979 | 16.69 | 2,720,119 |
| 2018-02-13 | Emster Kurt Von | Sale | 55,078 | 13.51 | 744,103 |
| 2018-02-07 | Emster Kurt Von | Sale | 40,763 | 12.35 | 503,423 |
| 2018-02-05 | Emster Kurt Von | Sale | 18,831 | 12.14 | 228,608 |
| 2018-02-02 | Emster Kurt Von | Sale | 2,000 | 12.11 | 24,220 |
| 2018-02-01 | Emster Kurt Von | Sale | 88,098 | 12.15 | 1,070,390 |
| 2018-01-31 | Emster Kurt Von | Sale | 12,300 | 12.23 | 150,429 |
| 2018-01-30 | Emster Kurt Von | Sale | 85,339 | 12.22 | 1,042,842 |
| 2018-01-25 | Emster Kurt Von | Sale | 39,438 | 12.18 | 480,354 |
| 2018-01-22 | Emster Kurt Von | Sale | 138,253 | 10.40 | 1,437,831 |
| 2018-01-19 | Emster Kurt Von | Sale | 130,584 | 10.25 | 1,338,486 |
| 2018-01-18 | Emster Kurt Von | Sale | 13,632 | 10.21 | 139,182 |
| 2018-01-05 | Emster Kurt Von | Sale | 4,300 | 10.21 | 43,903 |
| 2017-12-22 | Emster Kurt Von | Sale | 173,192 | 9.41 | 1,629,390 |
| 2017-11-10 | Emster Kurt Von | Sale | 50,048 | 9.26 | 463,394 |
| 2017-11-02 | Mcwherter Charles (SVP & Chief Scientific Officer) | Buy | 5,000 | 8.67 | 43,345 |
| 2017-11-02 | Goldfischer Carl (Director) | Sale | 18,000 | 8.66 | 155,880 |
| 2017-11-02 | Goldfischer Carl (Director) | Option Ex | 18,000 | 2.35 | 42,210 |
| 2017-11-01 | Emster Kurt Von | Sale | 4,320 | 9.26 | 39,981 |
| 2017-10-31 | Emster Kurt Von | Sale | 52,573 | 9.27 | 487,351 |
| 2017-10-30 | Emster Kurt Von | Sale | 6,636 | 9.26 | 61,449 |
| 2017-10-03 | Emster Kurt Von | Sale | 70,940 | 7.81 | 554,041 |
| 2017-10-02 | Emster Kurt Von | Sale | 37,936 | 7.93 | 300,832 |
| 2017-09-29 | Emster Kurt Von | Sale | 120,735 | 8.04 | 970,709 |
| 2017-09-28 | Emster Kurt Von | Sale | 90,389 | 8.15 | 736,670 |
| 2017-08-01 | Wills Robert James (Director) | Buy | 5,000 | 6.84 | 34,190 |
| 2017-07-20 | Mcwherter Charles (SVP & Chief Scientific Officer) | Buy | 5,000 | 7.43 | 37,130 |
| 2017-07-20 | Shah Sujal (Interim President & CEO) | Buy | 10,000 | 7.31 | 73,140 |
| 2017-07-19 | Emster Kurt Von | Buy | 153,846 | 6.50 | 999,999 |
| 2016-09-06 | Wills Robert James | Buy | 25,000 | 2.43 | 60,850 |
| 2016-04-15 | Omara Patrick J. (VP, Business Development) | Buy | 5,000 | 1.64 | 8,200 |
| 2016-04-15 | Mcwherter Charles (Sr. Vice President) | Buy | 3,000 | 1.68 | 5,040 |
| 2016-04-05 | Shah Sujal (Chief Financial Officer) | Buy | 33,000 | 1.39 | 45,870 |
| 2016-04-04 | Shah Sujal (Chief Financial Officer) | Buy | 22,000 | 1.39 | 30,579 |
| 2015-09-11 | Goldfischer Carl | Sale | 15,467 | 2.76 | 42,735 |
| 2015-09-10 | Goldfischer Carl | Sale | 16,500 | 2.71 | 44,715 |
| 2015-09-09 | Goldfischer Carl | Sale | 14,762 | 2.76 | 40,743 |
| 2015-08-14 | Von Emster Kurt | Buy | 58,641 | 2.70 | 158,330 |
| 2015-08-13 | Von Emster Kurt | Buy | 31,359 | 2.68 | 84,167 |
| 2015-07-20 | Von Emster Kurt | Buy | 1,600,000 | 2.81 | 4,496,000 |
| 2015-05-18 | Shah Sujal (Chief Financial Officer) | Buy | 10,000 | 3.40 | 34,000 |
| 2015-05-18 | Van Wart Harold (President and CEO) | Buy | 7,500 | 3.30 | 24,772 |
| 2015-05-15 | Mcwherter Charles (Sr. Vice President) | Buy | 2,000 | 3.16 | 6,314 |
| 2014-09-16 | Shah Sujal (Chief Financial Officer) | Buy | 10,000 | 7.44 | 74,400 |
Insider trading activities including stock purchases, stock sales, and option exercises of NONE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cymabay Therapeutics, Inc. (symbol NONE, CIK number 1042074) see the Securities and Exchange Commission (SEC) website.